IN8bio
INAB
22 hedge funds and large institutions have $7.45M invested in IN8bio in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 4 closing their positions.
250% more capital invested
Capital invested by funds: $2.13M → $7.45M (+$5.32M)
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
54.92% more ownership
Funds ownership: 21.59% → 76.52% (+55%)
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
16% more funds holding
Funds holding: 19 → 22 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.66M |
| 2 |
6CM
683 Capital Management
New York
|
+$1.38M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$1.38M |
| 4 |
TCBWMS
Texas Capital Bank Wealth Management Services
Dallas,
Texas
|
+$45.2K |
| 5 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$34.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BIOS Capital Management
Fort Worth,
Texas
|
-$63.2K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$59.1K |
| 3 |
Jane Street
New York
|
-$56.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$53.7K |
| 5 |
Two Sigma Investments
New York
|
-$40.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citigroup
New York
| – | -$106 | -49 | Closed |
|
INAB Hedge Fund Activity: Q4 2025 in Review
22 of the 8,232 institutional investors tracked by Wall St. Rank reported a position in IN8bio (INAB) for Q4 2025, worth a combined $7.45M — up 250% from $2.13M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new INAB positions and 4 closed out — a net gain of 3 holders — while 7 added to existing stakes and 6 trimmed.
The largest buyer was Alyeska Investment Group, adding an estimated $1.66M. The largest seller was BIOS Capital Management, cutting an estimated $63.2K.
- 22 institutional investors held IN8bio (INAB) as of Q4 2025, up from 19 in Q3 2025.
- Funds reported $7.45M of IN8bio stock for Q4 2025, up 250% quarter-over-quarter.
- 7 funds opened new IN8bio positions in Q4 2025 and 4 closed out, a net change of +3 holders.
- The largest IN8bio buyer in Q4 2025 was Alyeska Investment Group, an estimated $1.66M added.
- The largest IN8bio seller in Q4 2025 was BIOS Capital Management, an estimated $63.2K sold.
Based on aggregated 13F filings for Q4 2025.